Seelos Therapeutics (SEEL) News Today → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free SEEL Stock Alerts $2.34 +0.02 (+0.86%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 11:45 PM | prnewswire.comSeelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMay 14 at 3:13 PM | investorplace.comSEEL Stock Earnings: Seelos Therapeutics Beats EPS, Beats Revenue for Q1 2024May 14 at 11:45 AM | prnewswire.comSeelos Therapeutics Announces 1-for-8 Reverse Stock SplitMay 4, 2024 | seekingalpha.comSEEL Seelos Therapeutics, Inc.May 3, 2024 | marketwatch.comSeelos Therapeutics to Cut Workforce by 33%, Reduce Working HoursApril 29, 2024 | markets.businessinsider.comSeelos Therapeutics Appoints Richard Pascoe As Chairman Of The BoardApril 29, 2024 | prnewswire.comSeelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and CollaborationsMarch 22, 2024 | investorplace.comSEEL Stock Earnings: Seelos Therapeutics Beats EPS for Q4 2023March 20, 2024 | markets.businessinsider.comOptimistic Buy Rating for Seelos Therapeutics Amid Promising Drug Trial ResultsMarch 19, 2024 | markets.businessinsider.comSeelos: Phase 2/3 HEALEY ALS Trial Fails To Meet Statistical Significance In EndpointsMarch 19, 2024 | marketwatch.comSeelos Therapeutics Shares Drop 47% After SLS-005 Trial Misses Primary EndpointsMarch 19, 2024 | markets.businessinsider.comNasdaq Down 100 Points; US Housing Starts Surge In FebruaryMarch 19, 2024 | msn.comCNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's WhyMarch 19, 2024 | reuters.comSeelos says ALS treatment fails in mid-stage studyMarch 19, 2024 | finance.yahoo.comUPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage studyMarch 19, 2024 | msn.comSeelos falls as lead drug fails in ALS trialMarch 19, 2024 | prnewswire.comSeelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)February 9, 2024 | thestreet.comSeelos Therapeutics Inc.February 1, 2024 | ca.finance.yahoo.comSeelos Therapeutics, Inc. (SEEL)January 31, 2024 | msn.comSeelos Therapeutics Issues Common Warrants to InvestorsJanuary 31, 2024 | msn.comSeelos Therapeutics Strikes $4M Direct Offering DealJanuary 26, 2024 | markets.businessinsider.comSeelos Therapeutics Announces $4 Mln Direct Offering And Private Placement Of SharesJanuary 26, 2024 | marketwatch.comSeelos Therapeutics Shares Hit 52-Week Low After Direct Offering PricesJanuary 26, 2024 | finance.yahoo.comSeelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesJanuary 22, 2024 | markets.businessinsider.comSeelos Therapeutics Says Received Minutes From End Of Phase II Meeting With FDAJanuary 22, 2024 | finance.yahoo.comSeelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002January 17, 2024 | finance.yahoo.comTherapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health RevolutionJanuary 16, 2024 | finance.yahoo.comSeelos Therapeutics, Inc. (SEEL) stock forecast and price targetJanuary 5, 2024 | morningstar.comSeelos Therapeutics Inc SEELJanuary 2, 2024 | markets.businessinsider.comSeelos Therapeutics: ISS Recommends Stockholders Vote For All Proposals - Quick FactsJanuary 2, 2024 | finance.yahoo.comLeading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024December 22, 2023 | finance.yahoo.comSeelos Therapeutics, Inc. Releases Letter to its StockholdersDecember 20, 2023 | finance.yahoo.com11 Most Promising Psychedelic Stocks According to Hedge FundsDecember 18, 2023 | msn.comSeelos Therapeutics files for $250M mixed shelfDecember 16, 2023 | msn.comSeelos Therapeutics (SEEL) Price Target Increased by 2900.00% to 122.40December 4, 2023 | finance.yahoo.comInsider Spends US$100k Buying More Shares In Seelos TherapeuticsDecember 2, 2023 | finance.yahoo.comInsider Buying: CFO Michael Golembiewski Acquires 83,000 Shares of Seelos Therapeutics Inc (SEEL)December 1, 2023 | finance.yahoo.comSeelos Therapeutics Announces Closing of Public OfferingDecember 1, 2023 | benzinga.comThinking about buying stock in Neximmune, ShiftPixy, Ampio Pharmaceuticals, Seelos Therapeutics, or Nio Inc?November 29, 2023 | benzinga.comThinking about buying stock in RedHill Biopharma, Mynaric, Energy Transfer LP, Seelos Therapeutics, or Petco Health and Wellness?November 29, 2023 | marketwatch.comSeelos Therapeutics Shares Slide Premarket After Public OfferingNovember 29, 2023 | investorplace.comWhy Is Seelos Therapeutics (SEEL) Stock Down 42% Today?November 28, 2023 | markets.businessinsider.comSeelos Therapeutics Announces Pricing Of $5.55 Mln Public Offering; Stock DropsNovember 28, 2023 | msn.comSeelos Therapeutics commences a public offering of its sharesNovember 28, 2023 | finance.yahoo.comSeelos Therapeutics Announces Proposed Public OfferingNovember 28, 2023 | msn.comSeelos stock falls 23% following 1-for-30 reverse splitNovember 28, 2023 | msn.comSeelos Therapeutics, Iterum Therapeutics among healthcare moversNovember 28, 2023 | marketbeat.comTrading was temporarily halted for "SEEL" at 07:11 PM with a stated reason of "News pending."November 27, 2023 | msn.comDefense Dept. Funds Ketamine Study For PTSD Treatment In 600 Service Members & VeteransNovember 27, 2023 | markets.businessinsider.comSeelos' SLS-002 To Be Included In DOD's Trial To Evaluate Potential Treatments For PTSD Get Seelos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter. Email Address A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x! Just click here to learn how you can access this coin right now. SEEL Media Mentions By Week SEEL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SEEL News Sentiment▼0.130.54▲Average Medical News Sentiment SEEL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SEEL Articles This Week▼72▲SEEL Articles Average Week Get Seelos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ZVSA News Today NEXI News Today KZIA News Today PTPI News Today DRUG News Today SNPX News Today CPHI News Today LIPO News Today GNPX News Today GTBP News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SEEL) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersHow Biden has already won 2024Porter & Company348 million Americans lives to END as we know it?The Oxford ClubBiden Nomination CANCELED?The Freeport Society4 Cryptos BETTER than BitcoinTrue Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge AlertsInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seelos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.